Celldex Therapeutics Inc (CLDX) 13.69 $CLDX
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Celldex Therapeutics Is Down 8.9% (CLDX)
Comtex SmarTrend(R) - 2 hrs 45 mins ago
Two weeks ago on May 1st, 2014 Celldex Therapeutics (NASDAQ:CLDX) reported earnings and analysts, on average, expected a loss of $0.27 on sales of $337.0 thousand. The company actually reported a loss of $0.33 per share on sales of $416.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Since the company's report, shares of Celldex Therapeutics have fallen from $14.64 to $13.33, representing a loss of 8.9% in the past 18 days.
Recognitions, Agreements, Study Results, Data Presentations, and Financial Results - Analyst Notes on Baxter, Incyte, Isis, Celldex Therapeutics, Inc. and Agilent
PR Newswire - Mon May 19, 6:50AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2608-100free.
This Week in Biotech: Celldex Buddies Up While Isis' Experimental Diabetes Therapy Impresses
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 12:18PM CDT
With the SPDR S&P Biotech Index up 15% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
This Beaten-Down Stock Is Ready to Rebound
at The Street - Fri May 16, 8:28AM CDT
Consider buying this oversold stock as it gears up for a big move higher.
Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study.
Could Bristol-Myers End Up Acquiring Celldex?
Todd Campbell, The Motley Fool - Motley Fool - Thu May 15, 1:30PM CDT
Celldex 's shares jumped by more than a quarter following news that Bristol-Myers has paid Celldex $5 million up front and will pay half of development costs for a new study that teams Bristol's PD-1 drug nivolumab up with Celldex's promising...
Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - Thu May 15, 1:18PM CDT
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen.
36.6% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Wed May 14, 4:45PM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 2 months, Celldex Therapeutics has returned 36.56% as of today's recent price of $15.74.
Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 26.94% Rise
Comtex SmarTrend(R) - Wed May 14, 4:16PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $12.85 to a high of $15.97. Yesterday, the shares gained 26.9%, which took the trading range above the 3-day high of $13.69 on volume of 9.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why bluebird bio, Celldex Therapeutics, and MannKind Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed May 14, 4:15PM CDT
Despite a slower, but still steady stream of earnings reports, ongoing merger and acquisition rumors in the pharmaceutical sector, and mixed economic data, investors decided today would be the day to push the broad-based S&P 500 lower and lock...
Celldex Therapeutics Announces Varlilumab (CDX-1127) Phase 1 Clinical Data to be Presented at ASCO Annual Meeting 2014
GlobeNewswire - Wed May 14, 4:01PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago. The abstracts accepted for poster presentation are listed below. In addition, the data will be discussed during a Poster Highlight Session entitled "Modulating the Anti-tumor Immune Response" by Dr. Cassian Yee of The University of Texas MD Anderson Cancer Center on Monday, June 2, 2014 from 5:15 to 5:30 p.m. CDT.
Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets
ACCESSWIRE - Wed May 14, 2:50PM CDT
Whitefish, MT / May 14, 2014 / Pharmaceutical companies big and small are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are receiving the praise of analysts as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465. Shares of Celldex Therapeutics (NASDAQ: CLDX) are chugging ahead by 25 percent on Wednesday after striking a deal with Bristol-Myers Squibb (NYSE: BMY) to collaborate on the clinical development of BMY's PD-1 investigational drug nivolumab in combination with Celldex's CD27-targeting drug candidate varlilumab.
Why Celldex Therapeutics Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Wed May 14, 1:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celldex Therapeutics , a clinical-stage...
Celldex, Bristol-Myers Cut Deal on Immuno-Oncology Combo Trial
Ben Fidler, The Motley Fool - Motley Fool - Wed May 14, 11:05AM CDT
Big pharmaceutical companies everywhere are playing the mix and match game to come up with the best possible combination of immunotherapy drugs to treat cancer. Hampton, NJ-based Celldex Therapeutics has become the latest beneficiary of that...
Why Celldex Therapeutics (CLDX) Stock Is Surging Today
at The Street - Wed May 14, 10:43AM CDT
Celldex Therapeutics (CLDX) surged Wednesday after the company announced a clinical trial collaboration with Bristol-Myers Squibb (BMY).
Bristol, Celldex Collaborating on Cancer Immunotherapy Study
at The Street - Wed May 14, 9:39AM CDT
The phase I/II study will combine Bristol's PD-1 checkpoint inhibitor nivolumab with Celldex's CD27-targeted antibody varlilumab, also known as CDX-1127.
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Barbarian At The Gate" Stock
at The Street - Wed May 14, 9:16AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab
Business Wire - Wed May 14, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex's CD27 targeting investigational antibody in a Phase 1/2 study. Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer (NSCLC), metastatic melanoma, ovarian, colorectal (CRC) and squamous cell head and neck cancers.
Post Earnings Update: Celldex Therapeutics Has Sunk 12.6% Lower in Past Week (CLDX)
Comtex SmarTrend(R) - Mon May 12, 12:05PM CDT
When Celldex Therapeutics (NASDAQ:CLDX) reported earnings a week ago on May 1st, 2014, analysts, on average, expected the company to report a loss of $0.27 on sales of $337.0 thousand. The company actually reported a loss of $0.33 per share on sales of $416.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Shares of Celldex Therapeutics have slipped from $14.64 to $12.79, representing a loss of 12.6%, since the company reported earnings 11 days ago.
Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)
at The Street - Fri May 09, 9:03AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Celldex Therapeutics Is Down 8.9% (CLDX)
Comtex SmarTrend(R) - 2 hrs 45 mins ago
Two weeks ago on May 1st, 2014 Celldex Therapeutics (NASDAQ:CLDX) reported earnings and analysts, on average, expected a loss of $0.27 on sales of $337.0 thousand. The company actually reported a loss of $0.33 per share on sales of $416.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Since the company's report, shares of Celldex Therapeutics have fallen from $14.64 to $13.33, representing a loss of 8.9% in the past 18 days.
Recognitions, Agreements, Study Results, Data Presentations, and Financial Results - Analyst Notes on Baxter, Incyte, Isis, Celldex Therapeutics, Inc. and Agilent
PR Newswire - Mon May 19, 6:50AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2608-100free.
This Week in Biotech: Celldex Buddies Up While Isis' Experimental Diabetes Therapy Impresses
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 12:18PM CDT
With the SPDR S&P Biotech Index up 15% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
This Beaten-Down Stock Is Ready to Rebound
at The Street - Fri May 16, 8:28AM CDT
Consider buying this oversold stock as it gears up for a big move higher.
Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study.
Could Bristol-Myers End Up Acquiring Celldex?
Todd Campbell, The Motley Fool - Motley Fool - Thu May 15, 1:30PM CDT
Celldex 's shares jumped by more than a quarter following news that Bristol-Myers has paid Celldex $5 million up front and will pay half of development costs for a new study that teams Bristol's PD-1 drug nivolumab up with Celldex's promising...
Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - Thu May 15, 1:18PM CDT
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen.
36.6% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Wed May 14, 4:45PM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 2 months, Celldex Therapeutics has returned 36.56% as of today's recent price of $15.74.
Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 26.94% Rise
Comtex SmarTrend(R) - Wed May 14, 4:16PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $12.85 to a high of $15.97. Yesterday, the shares gained 26.9%, which took the trading range above the 3-day high of $13.69 on volume of 9.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why bluebird bio, Celldex Therapeutics, and MannKind Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed May 14, 4:15PM CDT
Despite a slower, but still steady stream of earnings reports, ongoing merger and acquisition rumors in the pharmaceutical sector, and mixed economic data, investors decided today would be the day to push the broad-based S&P 500 lower and lock...
Celldex Therapeutics Announces Varlilumab (CDX-1127) Phase 1 Clinical Data to be Presented at ASCO Annual Meeting 2014
GlobeNewswire - Wed May 14, 4:01PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago. The abstracts accepted for poster presentation are listed below. In addition, the data will be discussed during a Poster Highlight Session entitled "Modulating the Anti-tumor Immune Response" by Dr. Cassian Yee of The University of Texas MD Anderson Cancer Center on Monday, June 2, 2014 from 5:15 to 5:30 p.m. CDT.
Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets
ACCESSWIRE - Wed May 14, 2:50PM CDT
Whitefish, MT / May 14, 2014 / Pharmaceutical companies big and small are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are receiving the praise of analysts as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465. Shares of Celldex Therapeutics (NASDAQ: CLDX) are chugging ahead by 25 percent on Wednesday after striking a deal with Bristol-Myers Squibb (NYSE: BMY) to collaborate on the clinical development of BMY's PD-1 investigational drug nivolumab in combination with Celldex's CD27-targeting drug candidate varlilumab.
Why Celldex Therapeutics Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Wed May 14, 1:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celldex Therapeutics , a clinical-stage...
Celldex, Bristol-Myers Cut Deal on Immuno-Oncology Combo Trial
Ben Fidler, The Motley Fool - Motley Fool - Wed May 14, 11:05AM CDT
Big pharmaceutical companies everywhere are playing the mix and match game to come up with the best possible combination of immunotherapy drugs to treat cancer. Hampton, NJ-based Celldex Therapeutics has become the latest beneficiary of that...
Why Celldex Therapeutics (CLDX) Stock Is Surging Today
at The Street - Wed May 14, 10:43AM CDT
Celldex Therapeutics (CLDX) surged Wednesday after the company announced a clinical trial collaboration with Bristol-Myers Squibb (BMY).
Bristol, Celldex Collaborating on Cancer Immunotherapy Study
at The Street - Wed May 14, 9:39AM CDT
The phase I/II study will combine Bristol's PD-1 checkpoint inhibitor nivolumab with Celldex's CD27-targeted antibody varlilumab, also known as CDX-1127.
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Barbarian At The Gate" Stock
at The Street - Wed May 14, 9:16AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab
Business Wire - Wed May 14, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex's CD27 targeting investigational antibody in a Phase 1/2 study. Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer (NSCLC), metastatic melanoma, ovarian, colorectal (CRC) and squamous cell head and neck cancers.
Post Earnings Update: Celldex Therapeutics Has Sunk 12.6% Lower in Past Week (CLDX)
Comtex SmarTrend(R) - Mon May 12, 12:05PM CDT
When Celldex Therapeutics (NASDAQ:CLDX) reported earnings a week ago on May 1st, 2014, analysts, on average, expected the company to report a loss of $0.27 on sales of $337.0 thousand. The company actually reported a loss of $0.33 per share on sales of $416.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Shares of Celldex Therapeutics have slipped from $14.64 to $12.79, representing a loss of 12.6%, since the company reported earnings 11 days ago.
Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)
at The Street - Fri May 09, 9:03AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
